Finnish registry links oral semaglutide to HbA1c and weight gains at 12 months
The analysis covered 7,249 adults with type 2 diabetes who had never previously used a GLP-1 receptor agonist.
MH
By Maren Holt · Senior Reporter, GLP-1
Jun 11 03:00 ETSource: news-medical.net
The wire
- 01A nationwide Finnish registry study of 7,249 GLP-1RA-naive adults with type 2 diabetes found once-daily oral semaglutide associated with 12-month improvements in HbA1c, body weight, lipid markers and ALT.
- 02Real-world data on the oral formulation helps prescribers set expectations for patients who decline injectables or cannot manage cold-chain storage.
- 03This is registry data without a randomized comparator, so the associations cannot establish causation and adherence and confounding remain open questions.
From the source
Read at news-medical.netOral semaglutide improves blood sugar, weight, and liver markers in real-world diabetes care
A nationwide Finnish registry study of 7,249 GLP-1RA-naïve adults with type 2 diabetes found that once-daily oral semaglutide was associated with 12-month improvements in HbA1c, body weight, lipid markers, and ALT.
